Document Detail


The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population.
MedLine Citation:
PMID:  22998368     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: The most common risk factors for heart failure are hypertension and myocardial infarction. Angiotensin receptor blockers (ARBs) attenuate the deleterious effects of angiotensin II. Valsartan is a once or twice daily ARB that is FDA-approved for hypertension, LV dysfunction post-myocardial infarction and congestive heart failure as both an adjunct in ACE-inhibitor tolerant, and alternative in ACE-I intolerant patients.
AREAS COVERED: This article presents a comprehensive review of the literature regarding the pharmacokinetics and pharmacodynamics of valsartan, with particular attention paid to the post-myocardial infarction population.
EXPERT OPINION: Valsartan is a safe, well-tolerated and readily titratable ARB. In addition to its vasodilatory effects there are pleotropic effects associated with the ARB such as modulation of a number of neurohormonal regulators, cytokines and small molecules. Given the clear evidence-based benefits above and beyond its hypertensive properties, it has the potential, if priced appropriately, to grow in its impact as a pharmacotherapeutic long after its patent expires.
Authors:
Cassandra D Benge; James A S Muldowney
Related Documents :
6607318 - Early versus late lateral ventricular enlargement following closed head injury.
15920178 - Cardioprotection with volatile anesthetics: mechanisms and clinical implications.
23981548 - Relationship between ambient fine particles and ventricular repolarization changes and ...
19787388 - Limb ischemic preconditioning reduces heart and lung injury after an open heart operati...
10803448 - Acute myocardial infarction--a late complication of intracoronary stent placement.
10879798 - Early onset heart failure in transgenic mice with dilated cardiomyopathy.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2012-09-24
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  8     ISSN:  1744-7607     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-17     Completed Date:  2013-03-28     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1469-82     Citation Subset:  IM    
Affiliation:
Nashville Veterans Affairs Medical Center, Cardiology Section, 1310 24th Avenue South, Nashville, TN 37212-263, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II / pharmacology
Angiotensin Receptor Antagonists / pharmacokinetics*,  pharmacology*
Angiotensin-Converting Enzyme Inhibitors / pharmacology
Dose-Response Relationship, Drug
Drug Evaluation
Humans
Hypertension / drug therapy
Myocardial Infarction / drug therapy*,  physiopathology
Randomized Controlled Trials as Topic
Risk Factors
Tetrazoles / chemistry,  pharmacokinetics*,  pharmacology*
Valine / analogs & derivatives*,  chemistry,  pharmacokinetics,  pharmacology
Grant Support
ID/Acronym/Agency:
HL-89400/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Tetrazoles; 11128-99-7/Angiotensin II; 137862-53-4/valsartan; 7004-03-7/Valine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ruthenium-Catalyzed Aldehyde Functionality Reshuffle: Selective Synthesis of E-2-Arylcinnamaldehydes...
Next Document:  Trifluoromethylation of ?-Haloketones.